Panelists discuss how CD38 antibody–based four-drug regimens are transforming frontline multiple myeloma treatment by improving efficacy, deepening and sustaining MRD responses, and expanding use across patient populations through individualized dosing—establishing a new standard of care while paving the way for integration of novel immunotherapies and potential shifts in transplant strategy.
EP. 1: Introduction/Treatment Overview of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
June 16th 2025Panelists discuss how subcutaneous anti-CD38 monoclonal antibodies are reshaping frontline multiple myeloma treatment by improving efficacy, tolerability, and patient convenience across both transplant-eligible and ineligible populations.
EP. 2: CEPHEUS Trial: Design/Baseline Characteristics
June 16th 2025Panelists discuss how recent data support the use of quadruplet regimens—including anti-CD38 antibodies—even in older or moderately frail patients with newly diagnosed multiple myeloma, shifting treatment decisions from transplant eligibility to functional status and depth of response.
EP. 3: CEPHEUS Trial: MRD Negativity
June 23rd 2025Panelists discuss updated American Society of Clinical Oncology (ASCO) data showing that adding a CD38 monoclonal antibody to frontline triplet therapy improves minimal residual disease (MRD) negativity and progression-free survival in standard and intermediate-risk multiple myeloma, while reinforcing the need for tailored strategies in high-risk patients.
EP. 4: CEPHEUS Trial: Efficacy in Transplant-Ineligible Patients
June 23rd 2025Panelists discuss updated American Society of Clinical Oncology (ASCO) data showing that 4-drug regimens significantly improve outcomes even in patients with transplant-ineligible multiple myeloma, with real-world dose modifications enabling broader use while maintaining efficacy and tolerability.
EP. 5: CEPHEUS Trial: Adverse Events
June 30th 2025Panelists discuss the manageable safety profile of 4-drug regimens in patients with transplant-eligible multiple myeloma, highlighting dose modifications such as weekly bortezomib and dexamethasone tapering to reduce adverse effects, alongside vigilant infection monitoring to optimize tolerability and quality of life.
EP. 6: Treatment Overview of Transplant-Eligible Newly Diagnosed Multiple Myeloma
June 30th 2025Panelists discuss the adoption of 4-drug regimens—including a CD38 monoclonal antibody—as the standard frontline therapy for patients with transplant-eligible multiple myeloma, emphasizing tailored modifications based on age and frailty, and evolving maintenance strategies that incorporate daratumumab to deepen and sustain responses post-transplant.
EP. 7: PERSEUS Trial: Design/Baseline Characteristics
July 7th 2025Panelists discuss the Perseus study, which compared daratumumab-based quadruplet therapy (Dara-VRD) with VRD alone in patients with newly diagnosed, transplant-eligible multiple myeloma, highlighting its focus on a generally fit population and demonstrating improved progression-free survival and deeper responses with the 4-drug regimen, while noting some limitations in applicability to patients with significant comorbidities.
EP. 8: PERSEUS Trial: MRD Negativity
July 7th 2025Panelists discuss updated American Society of Clinical Oncology (ASCO) data confirming that daratumumab-based quadruplet therapy (Dara-VRD) significantly improves progression-free survival (PFS) and sustains minimal residual disease (MRD) negativity in patients with newly diagnosed transplant-eligible multiple myeloma, reducing early relapses and reinforcing this regimen as the evolving standard of care with potential for unprecedented long-term outcomes.